Common Side Effects of Kisqali
Kisqali (ribociclib), used to treat HR+/HER2- advanced breast cancer, causes side effects in most patients. The most frequent include neutropenia (low white blood cells, affecting 74-97% depending on dose), leukopenia (59-94%), fatigue (41-70%), nausea (29-52%), diarrhea (21-35%), vomiting (16-29%), hair thinning (15-33%), and infections like upper respiratory issues (11-18%). These often lead to dose interruptions or reductions.[1][2]
Serious Side Effects and Warnings
Kisqali carries black box warnings for low white blood cell counts (neutropenia), which can be severe or fatal, and QT prolongation (heart rhythm changes), raising risks of sudden death. Monitor blood counts before each cycle and ECGs periodically. Other serious risks: liver enzyme elevations (up to 10% grade 3/4), lung inflammation (interstitial lung disease/pneumonitis, 0.4-3%), and blood clots (2-3%). Discontinue if QT interval exceeds 500 ms or severe lung issues occur.[1][2][3]
Side Effects by Body System
- Blood/Bone Marrow: Anemia (23-45%), lymphopenia (28-44%).
- Gastrointestinal: Constipation (19-27%), abdominal pain (14-20%), decreased appetite (16-31%).
- Skin/Hair: Rash (17-24%), alopecia (15-33%).
- Musculoskeletal: Back pain (12-20%), arthralgia (7-16%).
- Other: Headache (14-20%), cough (13-23%), insomnia (7-14%). Elderly patients face higher rates of fatigue, lymphopenia, and falls.[1][2]
How Long Do Side Effects Last?
Neutropenia peaks around day 7-14 of each 28-day cycle, resolving with dose holds (median 1 week). Fatigue and nausea often improve after weeks 1-2 but persist chronically in 10-20%. Hair thinning is usually mild and reversible post-treatment.[2][3]
Managing Kisqali Side Effects
Doctors adjust doses (start at 600 mg/day, reduce to 400 or 200 mg if needed), hold for grade 3/4 neutropenia until recovery, and use supportive care like anti-nausea meds or growth factors. Avoid strong CYP3A inhibitors/inducers, which worsen toxicity. Report fever, shortness of breath, or irregular heartbeat immediately.[1][3]
Side Effects in Combination Therapy
Kisqali pairs with aromatase inhibitors or fulvestrant; adding steroids or CDK4/6 peers like Ibrance or Verzenio shows similar profiles, but Kisqali has higher neutropenia (vs. Ibrance's higher diarrhea). No head-to-head trials, but real-world data confirms comparable overall tolerability.[2][3]
[1]: Kisqali Prescribing Information (Novartis)
[2]: FDA Label for Ribociclib
[3]: Drugs.com - Kisqali Side Effects